Adverum Biotechnologies (ADVM) Competitors $5.91 +0.22 (+3.87%) (As of 12/6/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ADVM vs. MREO, HUMA, VERV, ABVX, CRVS, PRTC, TERN, MGTX, YMAB, and ZVRAShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Mereo BioPharma Group (MREO), Humacyte (HUMA), Verve Therapeutics (VERV), ABIVAX Société Anonyme (ABVX), Corvus Pharmaceuticals (CRVS), PureTech Health (PRTC), Terns Pharmaceuticals (TERN), MeiraGTx (MGTX), Y-mAbs Therapeutics (YMAB), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Mereo BioPharma Group Humacyte Verve Therapeutics ABIVAX Société Anonyme Corvus Pharmaceuticals PureTech Health Terns Pharmaceuticals MeiraGTx Y-mAbs Therapeutics Zevra Therapeutics Adverum Biotechnologies (NASDAQ:ADVM) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation. Does the media prefer ADVM or MREO? In the previous week, Mereo BioPharma Group had 6 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 7 mentions for Mereo BioPharma Group and 1 mentions for Adverum Biotechnologies. Mereo BioPharma Group's average media sentiment score of 0.94 beat Adverum Biotechnologies' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adverum Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ADVM or MREO more profitable? Mereo BioPharma Group's return on equity of 0.00% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adverum BiotechnologiesN/A -65.14% -40.52% Mereo BioPharma Group N/A N/A N/A Do analysts rate ADVM or MREO? Adverum Biotechnologies currently has a consensus price target of $27.83, indicating a potential upside of 370.95%. Mereo BioPharma Group has a consensus price target of $7.40, indicating a potential upside of 96.29%. Given Adverum Biotechnologies' higher probable upside, research analysts plainly believe Adverum Biotechnologies is more favorable than Mereo BioPharma Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the MarketBeat Community prefer ADVM or MREO? Adverum Biotechnologies received 324 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 77.59% of users gave Mereo BioPharma Group an outperform vote while only 60.39% of users gave Adverum Biotechnologies an outperform vote. CompanyUnderperformOutperformAdverum BiotechnologiesOutperform Votes36960.39% Underperform Votes24239.61% Mereo BioPharma GroupOutperform Votes4577.59% Underperform Votes1322.41% Do insiders and institutionals have more ownership in ADVM or MREO? 48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 4.2% of Adverum Biotechnologies shares are owned by insiders. Comparatively, 4.1% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation and earnings, ADVM or MREO? Mereo BioPharma Group has higher revenue and earnings than Adverum Biotechnologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdverum Biotechnologies$1M122.94-$117.17M-$5.99-0.99Mereo BioPharma Group$10M58.49-$29.47MN/AN/A SummaryMereo BioPharma Group beats Adverum Biotechnologies on 10 of the 14 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.94M$3.05B$5.30B$8.36BDividend YieldN/A1.87%5.73%4.02%P/E Ratio-0.9941.52100.4917.35Price / Sales122.94309.001,242.2290.23Price / CashN/A175.2743.6438.70Price / Book0.723.994.864.98Net Income-$117.17M-$41.34M$120.83M$198.24M7 Day Performance-10.99%-0.46%0.55%0.80%1 Month Performance-26.13%-0.96%-0.15%4.98%1 Year Performance-34.34%32.24%33.44%29.77% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies3.6865 of 5 stars$5.91+3.9%$27.83+371.0%-41.5%$122.94M$1M-0.99190MREOMereo BioPharma Group2.8615 of 5 stars$3.65+1.1%$7.50+105.5%+87.6%$566.30M$10M0.0040Analyst ForecastNews CoveragePositive NewsHUMAHumacyte3.4618 of 5 stars$4.47-1.1%$13.00+190.8%+71.3%$562.59M$1.57M-3.37150News CoverageVERVVerve Therapeutics2.5075 of 5 stars$6.56+16.9%$25.75+292.5%-49.9%$555.40M$24.40M-2.46110ABVXABIVAX Société Anonyme2.641 of 5 stars$8.58+0.6%$39.80+363.9%-14.0%$543.07MN/A0.0061Analyst ForecastNews CoveragePositive NewsCRVSCorvus Pharmaceuticals2.5405 of 5 stars$8.38-7.8%$12.83+53.1%+391.7%$538.50MN/A-9.7730Positive NewsPRTCPureTech Health2.065 of 5 stars$22.00-0.9%$45.00+104.5%+29.4%$526.68M$3.33M0.00100News CoverageGap DownTERNTerns Pharmaceuticals4.5477 of 5 stars$6.19-0.8%$30.70+396.0%-3.8%$525.77M$1M-5.2940Analyst ForecastNews CoverageMGTXMeiraGTx4.5995 of 5 stars$6.70-1.0%$23.50+250.7%+25.6%$523.61M$14.02M-5.60300Positive NewsYMABY-mAbs Therapeutics3.8906 of 5 stars$11.62-2.5%$21.38+84.0%+53.9%$520.46M$84.82M-22.07150Analyst UpgradeAnalyst RevisionNews CoverageZVRAZevra Therapeutics3.1293 of 5 stars$9.71+4.1%$21.00+116.3%+78.0%$518.28M$24.49M-4.7465 Related Companies and Tools Related Companies MREO Alternatives HUMA Alternatives VERV Alternatives ABVX Alternatives CRVS Alternatives PRTC Alternatives TERN Alternatives MGTX Alternatives YMAB Alternatives ZVRA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADVM) was last updated on 12/8/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredUrgent warning about your moneyThe stock market is booming … And Bitcoin just hiked through the roof. But don't get fooled by the "good...Weiss Ratings | SponsoredElon declares war on company he co-founded!?Elon Musk is leading humanity into the new era of AI. He’s just received a fresh $6 billion in funding for ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADVM Stock Alerts